At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 46 enrolled
Drug / intervention
Doxil +1 moredrug
Likely dose
Doxil 30 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Bevacizumab and Doxil in the Treatment of Platinum-Resistant or Refractory Ovarian Cancer
In Brief
A Phase 2 clinical trial evaluating Doxil and Avastin for Ovarian Cancer. Completed, enrolled 46 participants across 3 sites.
Detailed Summary
The purpose of this research study is to test the safety, tolerability, and effectiveness of two chemotherapy drugs, pegylated liposomal doxorubicin (Doxil) and bevacizumab (Avastin). How Doxil is metabolized and excreted from the body will also be studied.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvarian Cancer
CountriesUnited States
CollaboratorsGenentech, Inc., NYU Langone Health
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2007
First PostedJul 2009
Primary CompletionDec 2010
Study CompletionAug 2011
TodayJul 2026
First PostedJul 23, 2009
Enrollment StartMar 1, 2007
Primary CompletionDec 1, 2010
Study CompletionAug 1, 2011
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 16.9 years ago
Interventions
Doxildrug
Open label study of Doxil given as 30 mg/m2 every three weeks by itself in cycle 1
Avastindrug
First agent (Doxil) will be following by Avastin 15 mg/kg on cycle 2 and every cycle thereafter until disease progression